NZ584165A - Identification and isolation of fetal cells and nucleic acids by using an antibody which binds an fetal nucleosome epitope associated with histone H3.1 - Google Patents

Identification and isolation of fetal cells and nucleic acids by using an antibody which binds an fetal nucleosome epitope associated with histone H3.1

Info

Publication number
NZ584165A
NZ584165A NZ584165A NZ58416508A NZ584165A NZ 584165 A NZ584165 A NZ 584165A NZ 584165 A NZ584165 A NZ 584165A NZ 58416508 A NZ58416508 A NZ 58416508A NZ 584165 A NZ584165 A NZ 584165A
Authority
NZ
New Zealand
Prior art keywords
fetal
antibody
biological sample
nucleic acids
nucleosome
Prior art date
Application number
NZ584165A
Other languages
English (en)
Inventor
Farideh Bischoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ584165A publication Critical patent/NZ584165A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ584165A 2007-09-21 2008-09-22 Identification and isolation of fetal cells and nucleic acids by using an antibody which binds an fetal nucleosome epitope associated with histone H3.1 NZ584165A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97439207P 2007-09-21 2007-09-21
PCT/US2008/077251 WO2009039507A2 (en) 2007-09-21 2008-09-22 Identification and isolation of fetal cells and nucleic acid

Publications (1)

Publication Number Publication Date
NZ584165A true NZ584165A (en) 2012-09-28

Family

ID=40468814

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584165A NZ584165A (en) 2007-09-21 2008-09-22 Identification and isolation of fetal cells and nucleic acids by using an antibody which binds an fetal nucleosome epitope associated with histone H3.1

Country Status (12)

Country Link
EP (1) EP2207879A4 (xx)
JP (1) JP2010539906A (xx)
KR (1) KR20100061539A (xx)
CN (1) CN101883851A (xx)
AU (1) AU2008302040A1 (xx)
BR (1) BRPI0817199A2 (xx)
CA (1) CA2699958A1 (xx)
IL (1) IL204585A0 (xx)
MX (1) MX2010003116A (xx)
NZ (1) NZ584165A (xx)
WO (1) WO2009039507A2 (xx)
ZA (1) ZA201001912B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476013B2 (en) * 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
JP5923035B2 (ja) 2009-03-24 2016-05-24 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
EP3660165B1 (en) 2009-12-22 2023-01-04 Sequenom, Inc. Processes and kits for identifying aneuploidy
ES2930180T3 (es) 2012-03-02 2022-12-07 Sequenom Inc Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
EP4008270A1 (en) 2012-06-22 2022-06-08 Preprogen LLC Method for obtaining fetal cells and fetal cellular components
JP2015521862A (ja) 2012-07-13 2015-08-03 セクエノム， インコーポレイテッド 非侵襲性の出生前診断に有用な母体サンプル由来の胎児核酸のメチル化に基づく富化のためのプロセスおよび組成物
EP2971100A1 (en) 2013-03-13 2016-01-20 Sequenom, Inc. Primers for dna methylation analysis
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11155805B2 (en) 2017-03-27 2021-10-26 Sekisui Medical Co., Ltd. Target nucleic acid concentration and recovery method using antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804614A1 (en) * 1994-03-29 1997-11-05 Genzyme Corporation Culture and isolation of fetal cells from maternal peripheral blood
WO2003070894A2 (en) * 2002-02-20 2003-08-28 University Of Virginia Patent Foundation A non-invasive diagnostic test utilizing histone modification markers
GB0211904D0 (en) * 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
US20050181429A1 (en) * 2003-04-03 2005-08-18 Monaliza Medical Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
US20040197832A1 (en) * 2003-04-03 2004-10-07 Mor Research Applications Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
US20070243549A1 (en) * 2006-04-12 2007-10-18 Biocept, Inc. Enrichment of circulating fetal dna

Also Published As

Publication number Publication date
WO2009039507A3 (en) 2009-06-18
IL204585A0 (en) 2010-11-30
MX2010003116A (es) 2010-08-03
AU2008302040A1 (en) 2009-03-26
CN101883851A (zh) 2010-11-10
CA2699958A1 (en) 2009-03-26
KR20100061539A (ko) 2010-06-07
JP2010539906A (ja) 2010-12-24
ZA201001912B (en) 2011-05-25
EP2207879A2 (en) 2010-07-21
BRPI0817199A2 (pt) 2014-10-14
WO2009039507A2 (en) 2009-03-26
EP2207879A4 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
NZ584165A (en) Identification and isolation of fetal cells and nucleic acids by using an antibody which binds an fetal nucleosome epitope associated with histone H3.1
Greco et al. Preimplantation genetic testing: where we are today
WO2007121276A3 (en) Enrichment of circulating fetal dna
WO2011142836A3 (en) Assays for the detection of genotype, mutations, and/or aneuploidy
WO2009102632A3 (en) Method for isolating cell free apoptotic or fetal nucleic acids
GRIFFITH‐JONES et al. Detection of fetal DNA in trans‐cervical swabs from first trimester pregnancies by gene amplification: A new route to prenatal diagnosis?
WO2010117694A3 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
WO2009114543A3 (en) Nucleic acid-based tests for prenatal gender determination
WO2011087760A3 (en) Processes and kits for identifying aneuploidy
WO2010141075A8 (en) Specific analysis of ketone and aldehyde analytes using reagent compounds, labeling strategies, and mass spectrometry workflow
GB2485850B (en) Methods and compositions for detecting copy number and chromosome aneuploidy by ligation probes and partitioning the ligated products prior to amplification
RU2014119996A (ru) Обнаружение, выделение и анализ редких клеток в биологических жидкостях
WO2008081451A3 (en) Methods and kits for analyzing genetic material of a fetus
IN2015DN03186A (xx)
Singh et al. Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled
WO2009049007A3 (en) Compositions, methods and systems for rapid identification of pathogenic nucleic acids
WO2009114579A3 (en) Reducing/oxidizing activity of maternal urine as indicator of fetal gender related characteristics
WO2007046108A3 (en) Methods and kits for analyzing genetic material of a fetus
WO2011008030A3 (ko) 핵산 검출용 크로마토그래피 시스템
WO2012027483A3 (en) Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood
WO2009004340A3 (en) Identification of ectopic pregnancies
JP2013533865A5 (xx)
ATE525485T1 (de) Nukleinsäureanalyseverfahren zur analyse des methylierungsmusters von cpg-inseln in unterschiedlichen proben
WO2009031818A3 (en) Biomarker for purification or identification of mesenchymal stem cells and methods of purification of mesenchymal stem cells by using it
WO2008051604A3 (en) Methods and compositions for determining whether a subject carries a disease associated gene mutation common in jewish populations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 SEP 2015 BY CPA GLOBAL

Effective date: 20130313

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

LAPS Patent lapsed